

This is a repository copy of *Network meta-analysis of (individual patient) time to event data alongside (aggregate) count data*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/136192/>

Version: Published Version

---

## **Monograph:**

Saramago Goncalves, Pedro Rafael [orcid.org/0000-0001-9063-8590](https://orcid.org/0000-0001-9063-8590), Chuang, Ling-Hsiang and Soares, Marta Ferreira Oliveira [orcid.org/0000-0003-1579-8513](https://orcid.org/0000-0003-1579-8513) (2014) Network meta-analysis of (individual patient) time to event data alongside (aggregate) count data. Discussion Paper. CHE Research Paper . Centre for Health Economics, University of York , York, UK.

---

## **Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

## **Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.

THE UNIVERSITY *of York*



**Network Meta-Analysis of (Individual  
Patient) Time to Event Data alongside  
(Aggregate) Count Data**

**CHE Research Paper 95**



# Network meta-analysis of (individual patient) time to event data alongside (aggregate) count data

<sup>1</sup>Pedro Saramago

<sup>2</sup>Ling-Hsiang Chuang

<sup>1</sup>Marta Soares

<sup>1</sup>Centre for Health Economics, University of York, UK

<sup>2</sup>Pharmerit International, Rotterdam, The Netherlands

January 2014

## **Background to series**

CHE Discussion Papers (DPs) began publication in 1983 as a means of making current research material more widely available to health economists and other potential users. So as to speed up the dissemination process, papers were originally published by CHE and distributed by post to a worldwide readership.

The CHE Research Paper series takes over that function and provides access to current research output via web-based publication, although hard copy will continue to be available (but subject to charge).

## **Disclaimer**

Papers published in the CHE Research Paper (RP) series are intended as a contribution to current research. Work and ideas reported in RPs may not always represent the final position and as such may sometimes need to be treated as work in progress. The material and views expressed in RPs are solely those of the authors and should not be interpreted as representing the collective views of CHE research staff or their research funders.

## **Further copies**

Copies of this paper are freely available to download from the CHE website [www.york.ac.uk/che/publications/](http://www.york.ac.uk/che/publications/). Access to downloaded material is provided on the understanding that it is intended for personal use. Copies of downloaded papers may be distributed to third-parties subject to the proviso that the CHE publication source is properly acknowledged and that such distribution is not subject to any payment.

Printed copies are available on request at a charge of £5.00 per copy. Please contact the CHE Publications Office, email [che-pub@york.ac.uk](mailto:che-pub@york.ac.uk), telephone 01904 321405 for further details.

Centre for Health Economics  
Alcuin College  
University of York  
York, UK  
[www.york.ac.uk/che](http://www.york.ac.uk/che)

© Pedro Saramago, Ling-Hsiang Chuang, Marta Soares

## Abstract

**Objectives:** Network meta-analysis (NMA) methods extend the standard pair-wise framework to allow simultaneous comparison of multiple interventions in a single statistical model. Despite published work on NMA mainly focussing on the synthesis of aggregate data (AD), methods have been developed that allow the use of individual patient-level data (IPD) specifically when outcomes are dichotomous or continuous. This paper focuses on the synthesis of IPD and AD time to event data, motivated by a real data example looking at the effectiveness of high compression treatments on the healing of venous leg ulcers.

**Methods:** This paper introduces a novel NMA modelling approach that allows IPD (time to event with censoring) and AD (event count for a given follow-up time) to be synthesised jointly by assuming an underlying, common, distribution of time to healing. Alternative model assumptions were tested within the motivating example. Model fit and adequacy measures were used to compare and select models.

**Results:** Due to the availability of IPD in our example we were able to use a Weibull distribution to describe time to healing; otherwise, we would have been limited to specifying a uniparametric distribution. Absolute effectiveness estimates were more sensitive than relative effectiveness estimates to a range of alternative specifications for the model.

**Conclusions:** The synthesis of time to event data considering IPD provides modelling flexibility, and can be particularly important when absolute effectiveness estimates, and not just relative effect estimates, are of interest.



## 1. Background

In clinical practice, and at a wider societal level, treatment decisions in medicine need to consider all relevant alternative health care technologies. Such decisions are ideally informed by evidence on the relative effectiveness of treatments generated by randomised controlled trials (RCTs) (which may be further used to inform estimates of cost-effectiveness). Using evidence from individual RCTs may limit informed decision making since studies usually only provide comparative evidence on two treatments, potentially missing other relevant technologies which are also treatment options. This limitation can be overcome if all RCTs evaluating interventions relevant to the treatment decision are considered collectively, for example, with the use of network meta-analysis (NMA). NMA is a well-established statistical technique that extends standard the pairwise meta-analysis framework to allow simultaneous comparison of multiple interventions in a single statistical model. (1, 2) This approach then produces relative effect estimates (and associated descriptions of uncertainty) for all treatments connected by the network of evidence – even where head-to-head trials for comparisons do not exist (indirect data).

### *NMA using individual patient data*

Published work on NMA mainly focuses on the synthesis of aggregate data (AD) (sometimes called summary data, e.g. group means and standard errors available from study reports) (3, 4); however, methods have been developed that allow use of individual patient-level data (IPD) in NMA (5-7). The appeal of including IPD in a NMA is that it is likely to reduce statistical heterogeneity across the network (and in this way help resolve possible inconsistencies); and it may also allow for subgroup effects to be estimated that could guide more personalised treatment decisions (5). The use of IPD, alone or in combination with AD, has been shown to improve inference in NMAs where the outcome of interest is dichotomous (or binary) by aiding convergence, and by providing unbiased treatment–covariate interactions [that would otherwise be affected by ecological bias (8)]. For continuous outcomes, IPD is likely to also lead to more precise estimates of treatment effects, even in the absence of treatment–covariate interactions (9).

### *NMA using time to event related outcome data*

Where individual studies present hazard ratios, these AD can be pooled directly using standard methods (analogous to pooling count data where relative effectiveness measures are the odds ratios or relative risks) (10). However, other AD outputs such as median/mean time to event (11) and cumulative counts of patients having the outcome event in a period of time (12) have also been meta-analysed in a network – by specifying an underlying time to event distribution hazard ratios can be generated from these outputs (13). Whereas IPD having been used in pairwise analysis (12), there has been limited development of methods in the NMA framework.

### *Developing a NMA combining AD and IPD data to synthesise time to event related outcomes*

This paper describes a modelling framework that combines AD and IPD in the synthesis of time to event related outcomes. This work was motivated by a NMA for which we had data from multiple RCTs comparing treatments for the healing venous leg ulcers. A proportion of the RCT data was available in IPD format (time to event and time to censoring), with the remaining data available as AD, i.e. count data. To maximally draw from the available data we aimed to statistically synthesise jointly the available AD and IPD, in this way generating better estimates and providing fuller characterisations of uncertainty to best inform decisions on the use of the treatments of interest.



## 2. Motivating example: high compression treatments for venous leg ulcers

The case study relates to compression systems aiming to deliver high compression (classified as  $\geq 40$  mmHg compression at the ankle) to promote venous leg ulcer healing. Available standardised systems are: two layer hosiery (HH), the four layer bandage (4LB), the short stretch bandage (SSB), the zinc paste bandage (ZINC), and the two layer bandage system (2LB). A detailed description is provided in Box A1 in Appendix with further details of these systems presented elsewhere (14).

Effectiveness evidence from RCTs was obtained from the most recent update of the relevant Cochrane review available to us (15), and from a recent multicentre RCT which compared 4LB with HH. All available RCT evidence was assessed for inclusion in the current NMA: a detailed process that has been reported elsewhere (14). The final NMA contained data from 16 RCTs on the relative effectiveness of high compression systems for the treatment of venous leg ulcers. Data for two of the 16 included RCTs (VenUS I and VenUS IV, hereby denominated studies 1 and 2) had full IPD data available (841 participants) which included time to healing or censoring for each participant, together with other individual-level characteristics such as treatment centre, ulcer duration and size and also patient mobility. For the remaining RCTs (1105 participants), aggregate data on the number of healed ulcers were extracted from the source review alongside information regarding treatment type, number of participants allocated to each treatment group, mean duration of follow-up (if this was not stated, trial duration was used), mean ulcer duration and size.


The 16 included RCTs described nine unique high compression treatments: the five standard treatments (4LB, SSB, ZINC, HH and the 2LB) and four *ad hoc* systems (14). The *ad hoc* group consisted of treatments deemed irrelevant to current clinical practice, and are not reported further (results can be provided upon request). These studies were, however, included in the NMA as their data may still be relevant, for example, in describing determinants of healing.

Table 1 describes the data available and Figure 1 presents the network between treatments formed by the evidence (14, 16-30). The most populated comparison was the 4LB vs. SSB comparison, informed by seven RCTs: six available as AD (16-20, 29) and one IPD (30). The link between the 2LB and 4LB was informed by two RCTs and each of the remaining six comparisons in the NMA were informed by AD extracted from one RCT for each comparison (Table 1).

**Table 1: Analytic dataset**

ID	Study	Treatment	Follow up (weeks)	Number patients	Mean duration (months)	Mean size (cm <sup>2</sup> )	Number healed	Evidence format available
16	Duby <i>et al</i> 1993 <sup>(16)</sup>	4LB	12	25	20.5	11.9	11	AD
		SSB	12	25	26.7	13.1	10	
17	Scriven <i>et al</i> 1998 <sup>(17)</sup>	4LB	52	32	13	13.3	17.6	AD
		SSB	52	32	21	8.3	18.24	
18	Partsch <i>et al</i> 2001 <sup>(18)</sup>	4LB	16	53	1.25	1.5	33	AD
		SSB	16	59	1	1.9	43	
19	Ukat <i>et al</i> 2003 <sup>(19)</sup>	4LB	12	44	--	17.7	13	AD
		SSB	12	45	--	12.2	10	
20	Franks <i>et al</i> 2004 <sup>(20)</sup>	4LB	24	74	2	5	59	AD
		SSB	24	82	2	3.5	62	
21	Junger <i>et al</i> 2004b <sup>(21)</sup>	SSB	12	60	5.57	5.95	19	AD
		HH	12	61	4.14	5.62	29	
22	Kralj <i>et al</i> 1996 <sup>(22)</sup>	4LB	24	20	7.9	18.6	7	AD
		<i>Ad hoc</i> : Ba	24	20	6.9	17.2	8	
23	Polignano <i>et al</i> 2004b <sup>(23)</sup>	4LB	24	39	--	10.1	29	AD
		ZINC	24	29	--	9.3	19	
24	Wilkinson <i>et al</i> 1997 <sup>(24)</sup>	4LB	12	17	--	11.2	8	AD
		<i>Ad hoc</i> : BHeH	12	18	--	8.6	8	
25	Colgan <i>et al</i> 1995 <sup>(25)</sup>	4LB	12	10	9.3	27.5	6	AD
		<i>Ad hoc</i> : BzeaH	12	10	66.5	48.5	7	
26	Blecken <i>et al</i> 2005 <sup>(26)</sup>	4LB	12	12	--	50.08	4	AD
		<i>Ad hoc</i> : HV	12	12	--	48.98	4	
27	Moffatt <i>et al</i> 2008 <sup>(27)</sup>	4LB	4	42	48.8	5.7	3	AD
		2LB	4	39	46.6	11.8	6	
28	Szewczyk <i>et al</i> 2010 <sup>(28)</sup>	4LB	12	15	--	6	9	AD
		2LB	12	16	--	5.3	10	
29	Wong <i>et al</i> 2012 <sup>(29)</sup>	4LB	24	107	--	--	72	AD
		SSB	24	107	--	--	77	
30	Iglesias <i>et al</i> 2004 <sup>(30)</sup>	4LB	52	195	3	3.81	107	IPD
		SSB	52	192	3	3.82	86	
14	Ashby <i>et al</i> 2013 <sup>(14)</sup>	4LB	52	224	12.29	9.30	157	IPD
		HH	52	230	10.82	9.41	163	

AD – aggregate-level data; IPD – individual patient data; 4LB, SSB, HH, Zinc paste, 2LB and the *ad hoc* systems Ba, BHeH, BzeaH, HV as described in Box A1 in Appendix



**Figure 1: Network of RCTs**

In the network, a unique treatment category is indicated by a circle. Arrows between circles indicate that these treatments had been compared in a trial (trials are identified using '[ ]', numbered as in column 'ID' in Table 1. (4LB, SSB, HH, Ba, Zinc paste, BHeH, BzeaH, HV and 2LB as described in Box A1 in Appendix)

### 3. Methods

We first describe in detail the modelling framework for our main analysis, *model A*. We then detail the process of evaluating alternative assumptions to this model, thus highlighting and challenging specific assumptions of the modelling framework proposed. All synthesis was conducted in a Bayesian framework.

#### 3.1. Statistical model for the data

We describe *model A* in two interrelated parts [analogous to Sutton *et al* (31) and Saramago *et al* (5)]: *part I* describes the modelling of the IPD and *part II* the modelling of the AD.

*Model A, part I- modelling the IPD studies, controlling for baseline covariates*

$$\begin{aligned} t_{ijk} &\sim \text{Weibull}(s, h_{ijk}) I(t_{ijk}^c) \\ \log(h_{ijk}|Z_{ij}) &= \begin{cases} \mu_b^{IPD} + \gamma_j^c + \beta_0^m \cdot Z_{ij} & \mathbf{b} = \mathbf{A}, \mathbf{B}, \mathbf{C}, \dots \text{ if } \mathbf{k} = \mathbf{b} \\ \mu_b^{IPD} + d_{Ak} + d_{Ab} + \gamma_j^c + \beta_0^m \cdot Z_{ij} & \text{ if } k \text{ alphabetically after } b \end{cases} \quad (\text{A1}) \\ Z_{ij} &\sim N(\mathbf{a}^m, \mathbf{b}^m) \quad \gamma_j^c \sim N(\mathbf{0}, \tau) \quad \gamma \sim N(\mathbf{0}, \tau) \end{aligned}$$

Time to ulcer healing ( $t_{ijk}$ ) of the  $i^{th}$  participant in the  $j^{th}$  study and in the  $k^{th}$  treatment arm was assumed to be Weibull distributed (32) with *shape*<sup>1</sup> parameter,  $s$ , and *scale* parameter,  $h_{ijk}$ . For some participants, time to event was not observed, and these observations were censored at the time the participant last had trial data recorded,  $t_{ijk}^c$ . The baseline hazard function, linear on the log-scale, was modelled as a function of the log-hazard of an event for the baseline treatment  $b$ ,  $\mu_b^{IPD}$ , of treatment effects,  $d_{bk}$ , and of a set of baseline regression terms,  $\beta_0^m \cdot Z_{ij}$ , where  $\beta_0^m$  are the covariate effects of a set  $Z_{ij}$  of  $m$  ( $=4$ ) regressors available in the IPD data sets (14): the log of the baseline ulcer area and duration (in months) (both centred around its mean value); and two dummy variables ('walks with difficulty' and 'immobile') referring to participant mobility (reference category is 'walks freely'). The effects of these covariates on the hazard of healing were assumed to be equal in both IPD studies (i.e. the coefficient of each covariate was constant). Due to the existence of missing covariate information for some individuals, a distributional assumption was imposed on the covariate values, indicating that  $Z_{ij}$  are Normally distributed with mean  $\mathbf{a}^m$  and precision  $\mathbf{b}^m$ , common across all IPD studies. This procedure assumes that the missing mechanism was 'at random'<sup>2</sup>, which enables the use of multiple imputation techniques through MCMC<sup>3</sup>. Additionally, to account for centre variability within each IPD study,  $\gamma_j^c$  was defined for each centre,  $c$ , in the  $j^{th}$  study, these were combined using a common frailty effect,  $\gamma$ , described by a normal distribution with mean zero and precision  $\tau$ .

The treatment effects,  $d_{bk}$ , were log-hazard ratios for treatment  $k$  relative to the study-specific baseline treatment  $b$ , partitioned here as  $d_{bk} + d_{Ab}$ . Prior distributions were specified for

<sup>1</sup> The shape parameter of the Weibull distribution,  $s$ , can be interpreted directly as follows: i) if  $0 < s < 1$ , hazard rate decreases over time; ii) if  $s = 1$ , hazard rate is constant over time (hazard exponentially distributed); and if  $s > 1$ , it indicates that the hazard increases with time (Collet 2003).

<sup>2</sup> The missing-at-random assumption (sometimes called the ignorability assumption) considers that the probability that an observation is missing may depend on the observed values but not the missing values, as sufficient data has already been collected.

<sup>3</sup> When imputing missing information, MCMC generates independent draws of the missing data from its predictive distribution. Multiple imputation through MCMC techniques is attractive for exploratory or multi-purpose analyses involving a large number of estimands.

$\mu_b^{IPD} (\sim N(0, 10^6))$ , for each of the  $m$  regression coefficients  $\beta_0 (\sim N(0, 10^6))$ , for  $a^m (\sim N(0, 10^6))$  and  $b^m (\sim N(0, 10^6))$ , for the shared between centre variability  $\tau (\sim Gamma(0.01, 0.01))$  and for  $s (\sim Gamma(0.01, 0.01))$ . Vague prior distributions were given to  $d_{bk} \sim N(0, 10^6)$ . Note that  $d_{AA} = 0$ , where A was treatment 4LB, arbitrarily chosen as reference treatment.

*Model A, part II - modelling the AD studies*

$$\begin{aligned} r_{jk} &\sim Bin(p_{jk}, n_{jk}) \\ p_{jk} &= 1 - \exp(-h_{jk}^{AD} \cdot (t_{jk}^{AD})^s) \\ \log(ha_{jk}|X_{ij}) &= \begin{cases} \mu_{jb}^{AD} & b = A, B, C, \dots \text{ if } k = b \\ \mu_{jb}^{AD} + d_{Ak} + d_{Ab} & \text{ if } k \text{ alphabetically after } b \end{cases} \end{aligned} \quad (A2)$$

Within the AD studies, the observed number of participants with a healed study ulcer,  $r_{jk}$ , from the total number of individuals in the  $j^{th}$  trial and in the  $k^{th}$  treatment arm (intention to treat),  $n_{jk}$ , was assumed to be Binomially distributed. The underlying probabilities of an event for each arm and in each trial were represented by  $p_{jk}$ . In turn,  $p_{jk}$  was expressed as a function of the hazard,  $h_{jk}^{AD}$ , of follow-up time,  $t_{jk}^{AD}$ , and the shape parameter  $s$ . The hazard function, linear on the log-scale, was modelled by the baseline log-hazard of an event for treatment  $b$  in study  $j$ ,  $\mu_{jb}^{AD}$ , and by the log-hazard ratio for treatment  $k$  and baseline treatment  $b$ ,  $d_{bk} (= d_{Ak} + d_{Ab})$ . Note that there are parameters common to both model parts (equations A1 and A2), namely the log-hazard ratios and the shape parameter of the time to healing distribution. Prior distributions were specified for  $\mu_{jb}^{AD} (\sim N(0, 10^6))$ .

### 3.2. Alternative modelling assumptions

A set of assumptions made within *model A* were challenged; these are detailed below.

#### *Exploring between-study variation*

*Model A* assumed that each included RCT aimed to measure a common treatment effect (fixed-effect); however, it is likely that there was between-study variation. *Model B* included a random effect to characterise between-study heterogeneity, by considering  $\delta_{jbk} \sim N(d_{bk}, \sigma^2) \sim N(d_{Ak} + d_{Ab}, \sigma^2)$  rather than just  $d_{bk}$  – this is common to both *parts I* (eq. A1) and *II* (eq. A2).

#### *Time to healing distributions*

*Model A* used the Weibull distribution to describe time to healing. Our choice of survival distribution was limited as distributions such as the Log-Logistic or the Log-Normal do not allow the probability of healing over time to be expressed in a closed form, and hence impede the approach proposed here for the joint synthesis of IPD and AD. Other distributions, such as the Gompertz, were not readily defined within the software used in this work (WinBugs/OpenBugs), specifically under censoring. Nonetheless, the goodness of fit could still be assessed in each IPD data source individually. To do so, we applied parametric regression survival-time models (32) to both IPD data sources (16, 24) independently (covariates and frailty effect considered, as in *model A*).

#### *Distributional shape parameter*

*Model A* assumes that the Weibull shape parameter of the hazard of healing was common to both IPD data sources. It is possible though that this parameter differed between studies, in which case hazard ratios could be affected. Thus, we implemented two alternative NMA models to ascertain

the impact of this assumption on the relative effectiveness estimates: *model C1* used the shape parameter from the first IPD study to describe the AD studies and *model C2* used the shape parameter from the second IPD study (14) to describe these same studies. Because *models C1* and *C2* represent simple modifications of *model A* we do not present these algebraically.

### Treatment-covariate associations

*Model A* uses baseline covariates to adjust for clinical heterogeneity in the IPD. To further explore the impact of covariates on the relative treatment effects (i.e. whether they were effect modifiers), and potentially help explain between-study heterogeneity, we also included interaction terms between alternative treatments and baseline ulcer area and duration— as described by Cooper *et al* 2009 (33) and Saramago *et al* 2012 (5). *Model D* assumed a regression (slope) coefficient for the interaction terms, this effect is common across treatments and thus common to *parts I* (eq. D1) and *II* (eq. D2). This assumption was data driven, as this was the only option we were able to implement with the data available (i.e. compared to assuming ‘exchangeability’ or ‘independence’) (33). Note that interaction estimates obtained are influenced by the full evidence base for which study mean covariate(s) values are available, including trials considering *ad hoc* treatments. Given *model D* is substantially different to *model A* we describe it algebraically here.

*Model D, part I- modelling the IPD studies*

$$\begin{aligned}
 t_{ijk} &\sim \text{Weibull}(s, h_{ijk}) I(t_{ijk}^c) \\
 \log(h_{ijk}|Z_{ij}) &= \begin{cases} \mu_b^{IPD} + \gamma_j^c + \beta_0^m \cdot Z_{ij} & b = A, B, C, \dots \text{ if } k = b \\ \mu_b^{IPD} + d_{Ak} + d_{Ab} + \gamma_j^c + \beta_0^m \cdot Z_{ij} + \beta^n \cdot X_{ij} & \text{ if } k \text{ alphabetically after } b \end{cases} \quad (D1) \\
 Z_{ij} &\sim N(a^m, b^m) \quad \gamma_j^c \sim N(0, \tau) \quad \gamma \sim N(0, \tau)
 \end{aligned}$$

Time to ulcer healing is modelled in the same way as in *model A*. A set of covariate-treatment interaction regression terms,  $\beta^n \cdot X_{ij}$ , are here defined, where  $\beta^n$  are the association effects, assumed common across studies and the same regardless of treatment (excluding control), corresponding to a set  $X_{ij}$  of  $n$  ( $=2$ ) covariates including the log of the baseline ulceration area and baseline ulcer duration (in months). For the remainder of the parameters of interest, prior distributions were assigned as in *model A*.

*Model D, part II - modelling the AD studies*

$$\begin{aligned}
 r_{jk} &\sim \text{Bin}(p_{jk}, n_{jk}) \\
 p_{jk} &= 1 - \exp(-h_{jk}^{AD} \cdot (t_{jk}^{AD})^s) \\
 \log(ha_{jk}|X_{ij}) &= \begin{cases} \mu_{jb}^{AD} & b = A, B, C, \dots \text{ if } k = b \\ \mu_{jb}^{AD} + d_{Ak} + d_{Ab} + \beta^n \cdot X_j & \text{ if } k \text{ alphabetically after } b \end{cases} \quad (D2) \\
 X_j &\sim N(e^m, f^m)
 \end{aligned}$$

The underlying probabilities of an event for each arm in each trial,  $p_{jk}$ , were regressed against  $n$  ( $=2$ ) a set  $X_{ij}$  of study-level covariates [the log of the baseline ulceration area and baseline ulcer duration (in months)]. Uninformative prior distributions were assigned to the regression coefficients,  $\beta^n$  ( $\sim N(0, 10^6)$ ), to  $e^m$  ( $\sim N(0, 10^6)$ ) and  $f^m$  ( $\sim N(0, 10^6)$ ). All other components of the model are as described for *model A*.

### **3.3. Model selection and implementation**

The NMA analyses were undertaken in the WinBUGs software (34). In all models the MCMC sampler was run for 10 000 iterations and these were discarded as 'burn-in'. Models were run for a further 5000 iterations, on which inferences were based. Chain convergence was checked. The WinBUGS code is included for reference in the Appendix. Within the NMA, goodness of fit was assessed using the deviance information criterion (DIC) (35). Results were presented using hazard ratio estimates (and associated credibility intervals, CrIs) and also using the probability of each compression system being the 'best' treatment in terms of being the most clinically effective (36).

The statistical software STATA (37) was used to fit alternative time to event distributions to the IPD datasets individually. Goodness of fit was assessed with the Akaike Information Criteria (AIC) statistic (38).

## 4. Results

Table 2 shows parameter estimates obtained for *model A* (first column) and alternative models testing its assumptions (*models B* to *D*, second to fifth columns). The results for *model A* highlight that the modelling framework proposed is feasible. The results of testing the assumptions are described next, in turn.

### **Exploring between-study variation**

Despite estimates of HRs from the random effect model (*model B*) being associated with wider CrIs than those from *model A* (as expected), point estimates were found to be fairly similar except for the comparison between HH vs. 4LB: HH is estimated to be more effective in *model B* (HR 1.63, 95% CrI 0.76-3.53) compared to *model A* (HR: 1.05, 95% CrI 0.85 to 1.29), although the CrI of the former includes the later. The treatment with the greatest estimated probability of healing was HH in *model B* (59%), rather than 2LB (72%) as in *model A*. Differences may be explained by any existing variation between studies of SSB vs. 4LB indirectly impacting on the evidence loop 4LB vs. SSB vs. HH. Baseline covariate effect estimates remained similar. However, note that the gain in quality fitting of the random-effects model compared to the fixed-effects is null (DIC: 5396.21 and 5396.22, respectively). Previous published work assessing evidence on the SSB vs. 4LB comparison (39) similarly found no evidence of between-study heterogeneity.

### **Time to healing distributions**

The Weibull was the time to healing distribution used in *model A*. Whilst we were limited in the use of other distributions, goodness of fit was explored by applying alternative time to event distributions to the IPD studies individually. Table 3 shows results of such analysis (AIC statistic). The best fitting distributions for both studies were the Log-Logistic and Log-Normal. Of the remaining, the Weibull and Gompertz distributions provided better fit than the Exponential; this was expected given the flexibility of these distributions in assuming increasing, decreasing or constant hazards over time. The Weibull was best in IPD study 2 and the Gompertz best in IPD study 1.

### **Distributional Weibull shape parameter of healing hazard**

The Weibull shape parameters estimated within *models C1* and *C2* indicate that in IPD study 1 (30) the hazard of healing was expected to decrease over time ( $s_1 = 0.93$ , 95% CrI 0.86-1.01), while in IPD study 2 (14) it is expected to increase ( $s_2 = 1.27$ , 95% CrI 1.17-1.38). Note that there is no overlap in the CrIs. However, results show that relative effectiveness estimates are robust to the range of assumptions tested: the estimated HRs did not differ between *models C1* and *C2*, and did not substantially differ from *model A*.

### **Treatment-covariate associations**

*Model D* tested the inclusion of interaction terms. Results (column 5 of Table 2) found that the covariates included did not appear to be treatment effect modifiers in this case study. However, estimating these two additional regression terms increased uncertainty in relative treatment effects estimates, specifically for ZINC and 2LB.



**Table 2: Parameter estimates from the alternative MTC synthesis models.**

		<i>Model A</i>			<i>Model B</i>			<i>Model C1</i>			<i>Model C2</i>			<i>Model D</i>		
<b>Hazard ratios</b>		HR median (95% CrI)		P	HR median (95% CrI)		P	HR median (95% CrI)		P	HR median (95% CrI)		P	HR median (95% CrI)		P
<b>Treatment effects</b>	<b>4LB</b>	---	---	5.5	---	---	1.4	---	---	6.2	---	---	5.7	---	---	4.3
	<b>SSB</b>	0.88	(0.76, 1.03)	0.4	0.96	(0.77, 1.22)	0.6	0.89	(0.77, 1.04)	0.6	0.89	(0.77, 1.04)	0.6	0.84	(0.70, 0.99)	0.2
	<b>HH</b>	1.05	(0.85, 1.29)	16.1	1.63	(0.76, 3.53)	59.2	1.03	(0.83, 1.27)	14.9	1.03	(0.84, 1.27)	15.0	1.03	(0.84, 1.28)	11.1
	<b>ZINC</b>	0.77	(0.41, 1.42)	6.2	0.78	(0.37, 1.62)	2.8	0.78	(0.41, 1.44)	6.5	0.78	(0.41, 1.43)	6.7	0.75	(0.03, 29.49)	17.5
	<b>2LB</b>	1.40	(0.65, 3.05)	71.9	1.39	(0.62, 3.30)	36.0	1.38	(0.66, 3.05)	71.8	1.38	(0.63, 3.04)	72.0	1.59	(0.61, 5.34)	67.0
<b>Baseline characteristics</b>	<b>Log area</b>	0.71	(0.66, 0.76)	---	0.71	(0.66, 0.76)	---	0.70	(0.65, 0.75)	---	0.70	(0.65, 0.75)	---	0.71	(0.65, 0.76)	---
	<b>Log duration</b>	0.92	(0.90, 0.94)	---	0.92	(0.90, 0.94)	---	0.92	(0.91, 0.94)	---	0.93	(0.91, 0.94)	---	0.92	(0.90, 0.94)	---
	<b>Difficulty in walking</b>	0.71	(0.60, 0.85)	---	0.73	(0.60, 0.86)	---	0.72	(0.60, 0.85)	---	0.72	(0.60, 0.85)	---	0.71	(0.60, 0.80)	---
	<b>Immobile</b>	0.67	(0.23, 1.52)	---	0.66	(0.23, 1.51)	---	0.72	(0.24, 1.65)	---	0.72	(0.25, 1.67)	---	0.68	(0.24, 1.59)	---
<b>Interactions</b>	<b>Log area</b>	---	---	---	---	---	---	---	---	---	---	---	---	1.00	(0.97, 1.10)	---
	<b>Log duration</b>	---	---	---	---	---	---	---	---	---	---	---	---	1.00	(0.99, 1.00)	---
	<b>Btw-centre SD</b>	0.04	(0.01, 0.13)	---	0.05	(0.01, 0.13)	---	0.05	(0.01, 0.15)	---	0.05	(0.01, 0.15)	---			---
	<b>Btw-study SD</b>	---	---	---	0.13	(0.01, 0.51)	---	---	---	---	---	---	---	---	---	---
	<b><math>\lambda(s)</math></b>	1.07	(1.01, 1.13)	---	1.07	(1.01, 1.14)	$\lambda_1^{**}$	0.93	(0.86, 1.01)	$\lambda_1$	0.93	(0.86, 1.01)	---	1.07	(1.01, 1.14)	---
							$\lambda_2$	1.27	(1.17, 1.38)	$\lambda_2^{**}$	1.27	(1.17, 1.38)				
	<b>DIC</b>	5396.2			5396.2			5371.2			5371.5			5377.4		

*Model A* – Fixed-effects NMA, Weibull model of IPD+AD; *model B* – Random-effects NMA, Weibull model of IPD+AD; *model C1* – Fixed-effects NMA, Weibull model of IPD+AD, shape parameter derived from IPD study 1 only; *model C2* – Fixed-effects NMA, Weibull model of IPD+AD, shape parameter derived from IPD study 2 only; *model D* – Fixed-effects NMA, Weibull model of IPD+AD, considering 2 treatment-effect modifiers

\*\* Shape parameter used in the synthesis model section for summary data.

4LB = four layer bandage; SSB = Short stretch bandage; HH = two layer hosiery; 2LB = two layer bandage;

HR = hazard ratios; CrI = credibility interval; SD = standard deviation; P = probability of being the best treatment choice in terms of healing (%); DIC – deviance information criteria

**Table 3: Goodness of fit (AIC statistics) of alternative time to ulcer healing models for IPD studies 1 and 2.**

<i>Time to event model</i>	Akaike Information Criteria (AIC)	
	IPD study 1 (22)	IPD study 2 (14)
<i>Weibull PH</i>	1102.1	1021.0
<i>Gompertz PH</i>	1072.5	1065.5
<i>Exponential PH</i>	1102.7	1068.4
<i>Log-Logistic AFT</i>	1026.1	971.8
<i>Log-Normal AFT</i>	1032.2	961.5

## 5. Discussion

This paper introduces a novel NMA modelling approach that allows IPD (time to event with censoring) and AD (event count for a given follow-up time) to be synthesised jointly, by assuming an underlying, common, distribution of time to healing. Available IPD is used directly to inform this distribution (likelihood). Studies reporting the number of participants healed (AD) are used to inform a probability parameter, and a Binomial likelihood was defined for this subset of the evidence-set. The probability of healing is then related (algebraically) to the common distribution of time to healing, by taking the duration of follow-up in each AD study into account. This modelling framework extends the approaches of Soares *et al* (13) and Woods *et al* (40) and is also a natural extension of previously published methodologies of synthesising IPD and AD jointly (5, 31). This work was motivated by a real data example looking at the effectiveness of high compression treatments on the healing of venous leg ulcers.

We found that the key strength of the use of IPD in this context (additional to the known advantages described in the introduction) was the flexibility in modelling these data allowed. For example, had all evidence been available as AD, the modelling process would have been limited to the specification of uniparametric distributions for time to healing [i.e. the Exponential, with constant healing hazard over time, as employed in Soares *et al* (13) and Woods *et al* (40)]. In our motivating example, the Exponential distribution was shown to be less adequate than other distributions in describing the time to event data in the studies for which IPD was available. The availability of IPD allowed using a more complex distribution for time to event outcomes to be implemented, in this case the Weibull. This may be of particular importance when absolute effectiveness estimates, and not just relative effect estimates, are of interest – and especially where results may need to be extrapolated beyond the follow-up time horizon.

We note that even with this flexibility offered by the use of IPD we were, in practice, limited to using the Weibull distribution. Given this limitation, the synthesis of time to event data will still often require the use of potentially suboptimal distributional assumptions, in which case estimates obtained may be biased. We suggest further research, perhaps focuses on using numerical analysis techniques within the NMA, to try and resolve this issue.

This work was also relevant to once more highlight the importance of considering IPD when wanting to either include baseline characteristics or control for treatment-effect modifiers. The first relates to potential heterogeneity in the baseline hazard, which cannot be explicitly explored with AD only (this is important when analyses aim to explore determinants of baseline hazard, for example). In doing so, and analogously to what is commonly undertaken in related methodologies such as IPD meta-analysis, in this study we assumed a common effect of baseline covariates on the hazard of healing across IPD studies. The second relates to treatment-covariate interactions, that are generally acknowledged to be best estimated using IPD, as ecological bias can be avoided (8). For the proportion of evidence only available as AD, the model here implemented considered study level mean covariate values. Nonetheless, not all studies provided information for these, and imputation was undertaken (imputation is naturally done through the MCMC, and assumes values are ‘missing at random’).

In our work we assumed the shape parameter of the Weibull time to event distribution to be common across studies. However, assumption testing proved this not to be valid, in this way highlighting the importance of evaluating any assumptions of similarity imposed across studies. Despite relative effectiveness estimates being mainly unaffected, such potential heterogeneity between studies should be explored and accounted for in analyses. Such assumptions of commonality also mean that information may be shared throughout the network, in which case

evidence on treatments other than those on our decision set (the five treatments of interest for which results were reported). This is the case of *model D* that makes use of all evidence (including *ad hoc* treatments) to estimate treatment-covariate interaction, which may indirectly affect the relative effectiveness estimates of interest.

In summary, by allowing flexibility in specifying survival distributions and in dealing and considering potential existing heterogeneity more fully (41), the use of IPD in a time to event outcome setting is particularly useful in guiding HTA decision making. This work also emphasises the value of including anonymised IPD in evidence synthesis work. There is increasing focus on promoting data sharing (42, 43) and this example highlights how use of IPD allows the development of more informative and flexible models that are better able to summarise existing evidence. However, it is important to acknowledge that accessing and analysing IPD can be time consuming and may cause delay. The process needs to be well planned and implemented. In our case both sources of IPD were easily accessed and that directly facilitated the conduct of these analyses and the associated methodological work presented here.

## 6. References

1. Bucher H, Guyatt G, Griffith L, Walter S. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. *Journal of Clinical Epidemiology*. 1997;50(6):683-91.
2. Sutton A, Ades A, Cooper N, Abrams K. Use of indirect and mixed treatment comparisons for technology assessment. *Pharmacoeconomics*. 2008;26(9):753-67.
3. Saramago P, Manca A, Sutton AJ. Deriving input parameters for cost-effectiveness modelling: taxonomy of data types and approaches to their statistical synthesis. *Value in Health*. 2012;15(5):639-49.
4. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: A generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. *Medical Decision Making : an International Journal of the Society for Medical Decision Making*. 2013 Jul;33(5):607-17. Epub 2012/10/30.
5. Saramago P, Sutton AJ, Cooper NJ, Manca A. Mixed treatment comparisons using aggregate- and individual-participant level data. *Stat Med*. 2012;10;31(28):3516-36.
6. Jansen J, Cope S. Network meta-analysis of individual and aggregate level data. *Value in Health*. 2012 June;15(4):A159.
7. Donegan S, Williamson P, D'Alessandro U, Garner P, Smith C. Combining individual patient data and aggregate data in mixed treatment comparison meta-analysis: Individual patient data may be beneficial if only for a subset of trials. *Stat Med*. 2013 15 Mar;32(6):914-30.
8. Berlin J, Santanna J, Schmid C, Szczech L, Feldman H. Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head. *Stat Med*. 2002 15 Feb;21(3):371-87.
9. Riley R, Lambert P, Staessen J, Wang J, Gueyffier F, Thijs L, Bouët F. Meta-analysis of continuous outcomes combining individual patient data and aggregate data. *Stat Med*. 2008 20 May;27(11):1870-93.
10. Sutton AJ. *Methods for Meta-Analysis in Medical Research*. Chichester; New York:J. Wiley;2000. xvii, 317 p. p.
11. Welton NJ, Willis SR, Ades AE. Synthesis of survival and disease progression outcomes for health technology assessment of cancer therapies. *Research Synthesis Methods*. 2010;1(3-4):239-57.
12. Smith C, Williamson P, Marson A. An overview of methods and empirical comparison of aggregate data and individual patient data results for investigating heterogeneity in meta-analysis of time-to-event outcomes. *J Eval Clin Pract*. 2005 October;11(5):468-78.
13. Soares MO, Dumville JC, Ades AE, Welton NJ. Treatment comparisons for decision making: facing the problems of sparse and few data. *Journal of Royal Statistical Society - Series A (Statistics in Society)*. 2014.;177(1):259-79.

14. Ashby RL, Gabe R, Ali S, Saramago P, Chuang LH, Adderley U, Bland JM, Cullum NA, Dumville JC, Iglesias CP, Soares MO, Stubbs NC, Torgerson DJ. VenUS IV (Venous leg Ulcer Study IV): A randomised controlled trial of compression hosiery versus compression bandaging in the treatment of venous leg ulcers. *Health Technology Assessment* (forthcoming). 2014.
15. O'Meara S, Cullum N, Nelson EA, Dumville JC. Compression for venous leg ulcers. *Cochrane Database Syst Rev*. 2012;11:CD000265.
16. Duby T, Hoffman D, Cameron J, Doblhoffbrown D, Cherry G, Ryan T. A randomized trial in the treatment of venous leg ulcers comparing short stretch bandages, 4 layer bandage system, and a long stretch paste bandage system. *Wounds*. 1993 Nov-Dec;5(6):276-9.
17. Scriven J, Taylor L, Wood Rgn A, Bell P, Naylor A, London N. A prospective randomised trial of four-layer versus short stretch compression bandages for the treatment of venous leg ulcers. *Ann R Coll Surg Engl*. 1998;80(3):215-20.
18. Partsch H, Damstra R, Tazelaar D, Schuller-Petrovic S, Velders A, De Rooij M, Tjon Lim Sang R, Quinlan D. Multicentre, randomised controlled trial of four-layer bandaging versus short-stretch bandaging in the treatment of venous leg ulcers. *Vasa J Vasc Dis*. 2001;30(2):108-13.
19. Ukat A, Konig M, Vanscheidt W, Munter K. Short-stretch versus multilayer compression for venous leg ulcers: a comparison of healing rates. *J Wound Care*. 2003 Apr;12(4):139-43.
20. Franks P, Moody M, Moffatt C, Martin R, Blewett R, Seymour E, Hildreth A, Hourican C, Collins J, Heron A. Randomized trial of cohesive short-stretch versus four-layer bandaging in the management of venous ulceration. *Wound Repair Regen*. 2004 March/April;12(2):157-62.
21. Junger M, Wollina U, Kohnen R, Rabe E. Efficacy and tolerability of an ulcer compression stocking for therapy of chronic venous ulcer compared with a below-knee compression bandage: Results from a prospective, randomized, multicentre trial. *Curr Med Res Opin*. 2004 October;20(10):1613-23.
22. Kralj B, Kosicek M, editors. *Randomised comparative trial of single-layer and multi-layer bandages in the treatment of venous leg ulcer*. 5th European Conference on Advances in Wound Management; 1995; Harrogate, UK.
23. Polignano R, Bonadeo P, Gasbarro S, Allegra C. A randomised controlled study of four-layer compression versus Unna's Boot for venous ulcers. *J Wound Care*. 2004 Jan;13(1):21-4.
24. Wilkinson E, Buttfield S, Cooper S, Young E. Trial of two bandaging systems for chronic venous leg ulcers. *J Wound Care*. 1997 Jul;6(7):339-40.
25. Colgan MP, Teevan M, McBride C, O'Sullivan L, Moore D, Shanik G, editors. *Cost Comparisons in the Management of Venous Ulceration*. 5th European Conference on Advances in Wound Management; 1995; Harrogate, UK.
26. Blecken S, Villavicencio J, Kao T. Comparison of elastic versus nonelastic compression in bilateral venous ulcers: A randomized trial. *J Vasc Surg*. 2005 December;42(6):1150-5.
27. Moffatt C, Edwards L, Collier M, Treadwell T, Miller M, Shafer L, Sibbald G, Brassard A, McIntosh A, Reyzelman A, Price P, Kraus S, Walters SA, Harding K. A randomised controlled 8-

- week crossover clinical evaluation of the 3M Coban 2 Layer Compression System versus Profore to evaluate the product performance in patients with venous leg ulcers. *Int Wound J*. 2008 May;5(2):267-79.
28. Szewczyk M, Jawie A, Cierzniakowska K, Cwajda-Bialasik J, Moscicka P. Comparison of the effectiveness of compression stockings and layer compression systems in venous ulceration treatment. *Arch Med Sci*. 2010 October;6(5):793-9.
  29. Wong I, Andriessen A, Charles H, Thompson D, Lee D, So W, Abel MI. Randomized controlled trial comparing treatment outcome of two compression bandaging systems and standard care without compression in patients with venous leg ulcers. *J Eur Acad Dermatol Venereol*. 2012 January;26(1):102-10.
  30. Iglesias C, Nelson E, Cullum N, Torgerson D. VenUS I: a randomised controlled trial of two types of bandage for treating venous leg ulcers. *Health Technol Assess*. 2004 Jul;8(29):iii, 1-105.
  31. Sutton A, Kendrick D, Coupland C. Meta-analysis of individual- and aggregate-level data. *Stat Med*. 2008 28 Feb;27(5):651-69.
  32. Collett D. *Modelling Survival Data in Medical Research*. 2nd ed. Boca Raton, Fla.: Chapman & Hall/CRC;2003. 391 p. p.
  33. Cooper N, Sutton A, Morris D, Ades A, Welton N. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. *Stat Med*. 2009 30 Jun;28(14):1861-81.
  34. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility. *Stat Comput*. 2000 Oct;10(4):325-37.
  35. Spiegelhalter DJ, Best NG, Carlin BR, van der Linde A. Bayesian measures of model complexity and fit. *J Roy Stat Soc B*. 2002;64:583-616.
  36. Ades A, Sculpher M, Sutton A, Abrams K, Cooper N, Welton N, Lu G. Bayesian methods for evidence synthesis in cost-effectiveness analysis. *Pharmacoeconomics*. 2006;24(1):1-19.
  37. StataCorp. *Stata Statistical Software: Release 12*. College Station, TX: StataCorp LP2011.
  38. Akaike H, editor. *Information Theory and the Maximum Likelihood Principle*. 2nd International Symposium in Information Theory; 1973.
  39. O'Meara S, Tierney J, Cullum N, Bland J, Franks P, Mole T, Scriven M. Four layer bandage compared with short stretch bandage for venous leg ulcers: Systematic review and meta-analysis of randomised controlled trials with data from individual patients. *BMJ*. 2009 02 May;338(7702):1054-7.
  40. Woods B, Hawkins N, Scott D. Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial. *BMC medical research methodology*. 2010;10:54.

41. Espinoza M. *Heterogeneity in cost-effectiveness analysis: methods to explore the value of subgroups and individualised care in a collectively funded health system*: PhD Thesis. University of York; 2012.
42. MRC. Medical Research Council Data Sharing 2013 [cited 2013 October 2013]. Available from: <http://www.mrc.ac.uk/Ourresearch/Ethicsresearchguidance/datasharing/index.htm>.
43. NIHR-HTA. National Institute for Health Research - Health Technology Assessment Data Sharing 2013 [cited 2013 October]. Available from: <http://www.hta.ac.uk/funding/troubleshooting/#hta88>.



## Appendix

### Box A1: Description of main compression systems evaluated

1. Two layer hosiery, HH (smooth first layer, or understocking, providing light compression over which a second overstocking i.e. UK class II or III depending on the understocking slips on);
2. Four layer bandage, 4LB (an elastic system consisting of an orthopaedic wool layer plus three subsequent bandages);
3. Short stretch bandage, SSB (an inelastic bandage system where one to three rolls of bandage are applied over orthopaedic wool);
4. Zinc paste bandage, ZINC (an inelastic system consisting of a paste bandage often with a support bandage on top);
5. Two layer bandage system, 2LB (bottom layer with cohesive compression bandage - sub-compression wadding layer and cohesive bandage).

### WINBUGS code

This code relates to *model A* described above and is here described in a generic form for it to be easy for the user to modify and adapt to specific applications. Five datasets are required to fit the complete model: two containing constants for AD and IPD, two for both studies at IPD level and one for the AD evidence. All data should be loaded before the model is compiled. Because of size and agreements of use, the original data sets are not included in their entirety, but a couple of lines of data are supplied for each study/data combination for illustration purposes.

```
model {
### Part 1: Model for IPD 1 and IPD 2###
for(i in 1:n.subjects1) {
  #Weibull likelihood for IPD 1
  t.obs1[i] ~ dweib(shape,zu1[i])l(t.cen1[i],)
  #Model for IPD 1
  log(zu1[i]) <- mu1 + betac1[centre1[i]] + d[treat1[i]] - d[baseline1[i]] +
  beta_cov * cov1[i]
  cov1[i] ~dnorm(a1,b1)
}

#Vague priors for IPD 1
mu1~dnorm(0,1.0E-6)
a1~dnorm(0,1.0E-6)
b1~dgamma(0.01, 0.01)
for (i in 1:C1) {
  betac1[i] ~ dnorm(0.0,taua)
}

for(k in 1:n.subjects2) {
  #Weibull likelihood for IPD 2
  t.obs2[k] ~ dweib(shape,zu2[k])l(t.cen2[k],)
  #Model for IPD 2
  log(zu2[k]) <- mu2 + betac2[centre2[k]] + d[treat2[k]] - d[baseline2[k]] +
  beta_cov * cov2[i]
}
```

```

      cov2[i] ~dnorm(a2,b2)
    }

#Vague priors for IPD 2
mu2 ~ dnorm(0,1.0E-6)
a2~dnorm(0,1.0E-6)
b2~dgamma(0.01, 0.01)
for (i in 1:C2) {
  betac2[i] ~ dnorm(0.0,taua)
}

#Vague priors for baseline patient characteristics effects
beta_cov ~ dnorm(0,1.0E-6)

# Part 2: Model for aggregate data #
for(i in 1:n.agg.arm) {
  #Binomial likelihood for AD
  r[i]~dbin(pa[i],n[i])
  #Model for AD
  pa[i] <- 1 - exp( - zu.a[i] * pow(a.time[i], shape))
  log(zu.a[i]) <- mu.a[a.s[i]] + d[a.treat[i]] - d[a.base[i]]
}

#Vague priors for AD
for(j in 1:n.agg.trials) {
  mu.a[j]~dnorm(0,1.0E-6)
}

### Model for combining all estimates of treatment effect #
#Vague prior for shape parameter
shape ~ dgamma(0.01, 0.01)
#Vague priors for shared centre effect
betac.new ~ dnorm(0.0,taua)
taua ~ dgamma(0.01, 0.01)

#Vague prior for basic parameters
d[1]<-0
for (k in 2:treat) {
  d[k] ~ dnorm(0,1.0E-6)
}

}

### Dataset 1: Constants to define for IPD evidence###
# Number of participants in IPD 1 #
list(n.subjects1 = 386,
# Number of participants in IPD 2 #
n.subjects2 = 454,
# Number of treatments being evaluated
treat = 9,
# Number of centres in IPD 1

```

C1 = 9,  
 # Number of centres in IPD 1  
 C2 = 35)

### Dataset 2: Constants to define for AD evidence###

# Number of AD studies #  
 list(n.agg.trials = 14,  
 # Number of AD study arms #  
 n.agg.arms = 28)

### Dataset 3: IPD 1 ###

treat1[]	baseline1[]	t.obs1[]	t.cens1[]	cov1[]	centre1[]
1	1	3.50	0	1.95	3
1	1	2.33	0	1.94	9
2	1	NA	11.90	2.49	4
...	...	...	...	...	...
...	...	...	...	...	...

END

# treat1 = treatment arm (coded 1,2), baseline1 = reference treatment code,  
 # t.obs1 = time to event in months (under censoring), t.cens1 = time of censoring in months,  
 # cov1 = continuous covariate of interest (R+), centre1 = trial centre code (coded 1-9)

### Dataset 4: IPD 2 ###

treat2[]	baseline2[]	t.obs2[]	t.cens2[]	cov1[]	centre2[]
1	1	NA	21.28	5.15	1
1	1	1.15	0	0.94	16
3	1	8.41	0	2.31	2
...	...	...	...	...	...
...	...	...	...	...	...

END

# treat2 = treatment arm (coded 1,2), baseline2 = reference treatment code,  
 # t.obs2 = time to event in months (under censoring), t.cens2 = time of censoring in months,  
 # cov1 = continuous covariate of interest (R+), centre2 = trial centre code (coded 1-35)

### Dataset 5: AD evidence ###

a.s[]	a.treat []	r[]	n[]	a.base[]	a.time[]
1	1	11	25	1	12
1	2	10	25	1	12
...	...	...	...	...	...
...	...	...	...	...	...

END

# a.s = study number, a.treat = treatment arm code (coded from 1 to number of treatments),  
 # r = number of events in trial arm, n = number of patients in trial arm,  
 # a.base = reference treatment code, a.time = follow-up time of trial (in months)

### Initial values, either need specifying or generating for the below scalars and vectors ###

list(d = c(NA,0,0,0,0,0,0,0,0), mu1 = -1, mu2 = -1, mu.a = c(-1,-1,-1,-1,-1, -1,-1,-1,-1,-1, -1,-1,-1,-1),  
 beta\_cov = 0, shape = 1, betac.new = 0, betac1 = c(0,0,0,0,0, 0,0,0,0), betac2 = c(0,0,0,0,0, 0,0,0,0,0,0,  
 0,0,0,0,0, 0,0,0,0,0, 0,0,0,0,0, 0,0,0,0,0, 0,0,0,0,0))